Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Fireworks
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(82)
•••
Comment by JimmyJon Mar 03, 2021 6:40pm
268 Views
Post# 32711232

RE:RE:RE:RE:RE:Fireworks

RE:RE:RE:RE:RE:Fireworks
MrMugsy wrote:
JimmyJ wrote:

Yeah, that was all for today.  It was a formal press release though.  Wondering if Crow's message last night about a NR and fireworks was a coincidence?  Maybe more to come? 

https://antibethera.com/news/antibe-therapeutics-to-present-at-upcoming-virtual-investor-conferences/

 



Crow's comment is likely related more to the expected IND filing for OTENA.
Dan said it was weeks away on January 11th - so - if we look at the time he said weeks away for the shareholder update, March/April is likely our timeframe.
Hoping it's more likely in March - as this is a busy month for marketing the company.
An IND filing would come in handy at this time (IMO).





or...Crow was tipped there was going to be a NR today and he might have thought/assumed it was going to be what you just said.  :)  

Jokes aside, I agree we are due for news but having the cash in hand may change the timeline (unless the Nuance and bought deal was already part of the plan, but I don't believe it was).  They have bought themselves some time to get this right. Hopefully it won't take too long 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities